A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 79
- Registration Number
- NCT03238963
- Locations
- 🇺🇸
Trinity Research, Dothan, Alabama, United States
🇮🇹Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy
🇮🇹IRCCS Fondazione Bietti, Roma, Italy
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT03230097
- Locations
- 🇺🇸
Michigan Clinical Research Institute PC, Ann Arbor, Michigan, United States
🇺🇸Precise Research Centers, Flowood, Mississippi, United States
🇺🇸PRIME Clinic, New Haven, Connecticut, United States
This Study Tests How Healthy Men Tolerate Different Doses of BI1015550. The Study Also Tests How BI 1015550 is Taken up by the Body
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42
- Registration Number
- NCT03230487
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 259
- Registration Number
- NCT03210259
- Locations
- 🇺🇸
Universal Clinical Research, Hialeah, Florida, United States
🇺🇸Kansas City Dermatology, PA, Overland Park, Kansas, United States
🇺🇸MediSearch Clinical Trials, Saint Joseph, Missouri, United States
This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 83
- Registration Number
- NCT03210272
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice
- Conditions
- Hypertension
- Interventions
- Drug: subjects treated with telmisartan/hydrochlorothiazideDrug: Subjects treated with Telmisartan and amlodipineDrug: subjects treated with Telmisartan+hydrochlorothiazide double-pill combination groupDrug: subjects treated with telmisartan+amlodipine double pill
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT03205137
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan
This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is Tolerated
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT03206632
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Evaluation of Safety and Tolerability of Single Rising Doses of BI 473494 in Healthy Subjects
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT03195088
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each Other
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT03193307
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Specific Use-Result of Spiriva Respimat® in Asthmatics
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 193
- Registration Number
- NCT03188120
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan